Latest News and Press Releases

NurExone Welcomes Biopharma Executive Dr. Ram Petter to Drive Strategic Collaborations

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production